Pibrentasvir is an NS5A inhibitor antiviral agent.[1] In the United States and Europe, it is approved for use with glecaprevir as the combination drug glecaprevir/pibrentasvir (trade name Mavyret in the US and Maviret in the EU) for the treatment of hepatitis C.[2][3] It is sold by Abbvie.[citation needed]
References
- ^ Ng TI, Krishnan P, Pilot-Matias T, Kati W, Schnell G, Beyer J, et al. (May 2017). "In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir". Antimicrobial Agents and Chemotherapy. 61 (5): e02558–16. doi:10.1128/AAC.02558-16. PMC 5404558. PMID 28193664.
- ^ Johnson LA (August 3, 2017). "FDA OKs new drug to treat all forms of hepatitis C". Fox Business.
- ^ "Maviret: EPAR – Summary for the public" (PDF). European Medicines Agency. 2017-08-17. Archived from the original (PDF) on 2017-10-19. Retrieved 2017-10-19.
You must be logged in to post a comment.